From August 1, 2022 to October 31, 2022, the company has repurchased 2,023,515 shares, representing 9.75% for $5.58 million. With this, the company has completed the repurchase of 2,875,496 shares, representing 13.86% for $7.65 million under the buyback announced on June 2, 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.177 USD | +0.77% | +0.77% | +0.77% |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+0.77% | 18.4M | |
+32.36% | 695B | |
+26.51% | 568B | |
-4.40% | 361B | |
+19.46% | 330B | |
+3.50% | 283B | |
+16.34% | 239B | |
+6.68% | 204B | |
-9.08% | 198B | |
+8.62% | 168B |
- Stock Market
- Equities
- PMCB Stock
- News PharmaCyte Biotech, Inc.
- Tranche Update on PharmaCyte Biotech, Inc.'s Equity Buyback Plan announced on June 2, 2022.